RU2739318C2 - Пролекарство производного аминокислоты - Google Patents
Пролекарство производного аминокислоты Download PDFInfo
- Publication number
- RU2739318C2 RU2739318C2 RU2018140250A RU2018140250A RU2739318C2 RU 2739318 C2 RU2739318 C2 RU 2739318C2 RU 2018140250 A RU2018140250 A RU 2018140250A RU 2018140250 A RU2018140250 A RU 2018140250A RU 2739318 C2 RU2739318 C2 RU 2739318C2
- Authority
- RU
- Russia
- Prior art keywords
- carbonyl
- group
- oxy
- hexane
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/48—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing ten carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016083147 | 2016-04-18 | ||
| JP2016-083147 | 2016-04-18 | ||
| PCT/JP2017/016125 WO2017183734A1 (en) | 2016-04-18 | 2017-04-18 | Prodrug of amino acid derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018140250A RU2018140250A (ru) | 2020-05-19 |
| RU2018140250A3 RU2018140250A3 (enExample) | 2020-06-23 |
| RU2739318C2 true RU2739318C2 (ru) | 2020-12-22 |
Family
ID=58737797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018140250A RU2739318C2 (ru) | 2016-04-18 | 2017-04-18 | Пролекарство производного аминокислоты |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10464884B2 (enExample) |
| EP (1) | EP3445743B1 (enExample) |
| JP (2) | JP7045321B2 (enExample) |
| KR (1) | KR102444718B1 (enExample) |
| CN (1) | CN109071418B (enExample) |
| AU (1) | AU2017254266B2 (enExample) |
| BR (1) | BR112018069959B1 (enExample) |
| CA (1) | CA3019097C (enExample) |
| CY (1) | CY1124574T1 (enExample) |
| DK (1) | DK3445743T3 (enExample) |
| ES (1) | ES2886442T3 (enExample) |
| HR (1) | HRP20211277T1 (enExample) |
| HU (1) | HUE056046T2 (enExample) |
| IL (1) | IL262233B (enExample) |
| LT (1) | LT3445743T (enExample) |
| MX (1) | MX379567B (enExample) |
| MY (1) | MY195208A (enExample) |
| NZ (1) | NZ747061A (enExample) |
| PH (1) | PH12018502211A1 (enExample) |
| PL (1) | PL3445743T3 (enExample) |
| PT (1) | PT3445743T (enExample) |
| RS (1) | RS62515B1 (enExample) |
| RU (1) | RU2739318C2 (enExample) |
| SG (2) | SG11201808387PA (enExample) |
| SI (1) | SI3445743T1 (enExample) |
| SM (1) | SMT202100601T1 (enExample) |
| TW (1) | TWI738767B (enExample) |
| WO (1) | WO2017183734A1 (enExample) |
| ZA (1) | ZA201806444B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY195208A (en) * | 2016-04-18 | 2023-01-11 | Taisho Pharmaceutical Co Ltd | Prodrug of Amino Acid Derivative |
| JP7314494B2 (ja) * | 2017-10-17 | 2023-07-26 | 大正製薬株式会社 | アミノ酸誘導体のプロドラッグを含有する医薬 |
| JP7436385B2 (ja) * | 2018-04-24 | 2024-02-21 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | Ｈｉｖ成熟阻害活性を有する化合物 |
| CN109180712B (zh) * | 2018-08-08 | 2020-12-25 | 南京医科大学 | 一类2-茨醇的芳基硼酸酯衍生物及其应用 |
| CN108948077B (zh) * | 2018-08-09 | 2020-10-13 | 东华理工大学 | 一种α-磷酰化的α-氨基酸酯类化合物及其合成方法 |
| JPWO2022114135A1 (enExample) * | 2020-11-26 | 2022-06-02 | ||
| CN112409443B (zh) * | 2021-01-25 | 2021-04-27 | 潍坊科技学院 | 一种脯氨酸茨醇衍生物及其制备方法和在制备治疗心脑血管类疾病的药物中的应用 |
| CN114805104B (zh) * | 2021-01-29 | 2026-06-30 | 南京宁丹新药技术股份有限公司 | 一类氨基水杨酸类衍生物及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2315622C2 (ru) * | 2001-12-27 | 2008-01-27 | Тайсо Фармасьютикал Ко.,Лтд. | Производные 6-фторбицикло[3.1.0]гексана |
| WO2012068041A1 (en) * | 2010-11-18 | 2012-05-24 | Eli Lilly And Company | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002353845A1 (en) | 2001-11-23 | 2003-06-10 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| EP2123630B1 (en) | 2003-06-26 | 2012-07-25 | Taisho Pharmaceutical Co., Ltd | 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative |
| US8642777B2 (en) | 2009-11-19 | 2014-02-04 | Taisho Pharmaceutical Co., Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| WO2013062680A1 (en) | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| EP2857385B1 (en) * | 2012-06-01 | 2017-08-02 | Taisho Pharmaceutical Co., Ltd. | Prodrug of fluorine-containing amino acid |
| WO2015065983A1 (en) | 2013-10-29 | 2015-05-07 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of gastrointestinal infections |
| MY195208A (en) * | 2016-04-18 | 2023-01-11 | Taisho Pharmaceutical Co Ltd | Prodrug of Amino Acid Derivative |
-
2017
- 2017-04-18 MY MYPI2018703815A patent/MY195208A/en unknown
- 2017-04-18 PL PL17724459T patent/PL3445743T3/pl unknown
- 2017-04-18 SI SI201730877T patent/SI3445743T1/sl unknown
- 2017-04-18 EP EP17724459.7A patent/EP3445743B1/en active Active
- 2017-04-18 NZ NZ747061A patent/NZ747061A/en unknown
- 2017-04-18 ES ES17724459T patent/ES2886442T3/es active Active
- 2017-04-18 DK DK17724459.7T patent/DK3445743T3/da active
- 2017-04-18 BR BR112018069959-4A patent/BR112018069959B1/pt active IP Right Grant
- 2017-04-18 LT LTEPPCT/JP2017/016125T patent/LT3445743T/lt unknown
- 2017-04-18 SG SG11201808387PA patent/SG11201808387PA/en unknown
- 2017-04-18 PT PT177244597T patent/PT3445743T/pt unknown
- 2017-04-18 SG SG10202006019YA patent/SG10202006019YA/en unknown
- 2017-04-18 MX MX2018012442A patent/MX379567B/es unknown
- 2017-04-18 WO PCT/JP2017/016125 patent/WO2017183734A1/en not_active Ceased
- 2017-04-18 SM SM20210601T patent/SMT202100601T1/it unknown
- 2017-04-18 JP JP2018552900A patent/JP7045321B2/ja active Active
- 2017-04-18 CN CN201780024360.7A patent/CN109071418B/zh active Active
- 2017-04-18 TW TW106112946A patent/TWI738767B/zh active
- 2017-04-18 AU AU2017254266A patent/AU2017254266B2/en active Active
- 2017-04-18 CA CA3019097A patent/CA3019097C/en active Active
- 2017-04-18 RU RU2018140250A patent/RU2739318C2/ru active
- 2017-04-18 RS RS20211289A patent/RS62515B1/sr unknown
- 2017-04-18 KR KR1020187029353A patent/KR102444718B1/ko active Active
- 2017-04-18 HR HRP20211277TT patent/HRP20211277T1/hr unknown
- 2017-04-18 US US15/765,903 patent/US10464884B2/en active Active
- 2017-04-18 HU HUE17724459A patent/HUE056046T2/hu unknown
-
2018
- 2018-09-27 ZA ZA2018/06444A patent/ZA201806444B/en unknown
- 2018-10-09 IL IL262233A patent/IL262233B/en unknown
- 2018-10-16 PH PH12018502211A patent/PH12018502211A1/en unknown
-
2019
- 2019-07-15 US US16/511,349 patent/US10689327B2/en active Active
-
2020
- 2020-12-22 JP JP2020212361A patent/JP2021063095A/ja not_active Withdrawn
-
2021
- 2021-10-08 CY CY20211100876T patent/CY1124574T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2315622C2 (ru) * | 2001-12-27 | 2008-01-27 | Тайсо Фармасьютикал Ко.,Лтд. | Производные 6-фторбицикло[3.1.0]гексана |
| WO2012068041A1 (en) * | 2010-11-18 | 2012-05-24 | Eli Lilly And Company | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
Non-Patent Citations (1)
| Title |
|---|
| A. YASUHARA ET AL., Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): A potent and orally active group II mGluR antagonist with antidepressant-like potential, BIOORG. & MED. CHEM., 2006, vol. 14, no. 12, pp. 4193-4207. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10689327B2 (en) | Prodrug amino acid derivative | |
| TWI761961B (zh) | 稠合吡啶酮類化合物及其製備方法和應用 | |
| EP3675848B1 (en) | Spirocycle compounds and methods of making and using same | |
| JP2023502441A (ja) | 置換大環状化合物および関連する治療方法 | |
| EP3686196B1 (en) | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor | |
| CA2861150C (en) | Morphinan derivative | |
| EA038150B1 (ru) | Ингибиторы magl | |
| IL259862A (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| EP3515897A1 (en) | Piperazine carbamates and methods of making and using same | |
| RU2734475C2 (ru) | Разделение энантиомеров 3-этилбицикло [3.2.0] гепт-3-ен-6-она | |
| EP3283487A1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
| JP7314494B2 (ja) | アミノ酸誘導体のプロドラッグを含有する医薬 | |
| HK1260638A1 (en) | Prodrug of amino acid derivative | |
| HK1260638B (en) | Prodrug of amino acid derivative | |
| TW202615023A (zh) | 經取代之三環雜環磺醯胺衍生物及其用途 | |
| US20110021625A1 (en) | Neuronal cell death inhibitor | |
| WO2024059090A1 (en) | Phenalkylamines and methods of making and using the same |